Investors & Media
Ryvu Therapeutics has a track record of creating significant value for shareholders since its listing on the NewConnect market in 2011 and the subsequent IPO on the main market of Warsaw Stock Exchange in 2014. The company has delivered strong return on the combined $91M investment from private, public market investors, including over $36M raised in the Series I shares offering in July 2020. In December 2022, Ryvu closed an equity offering with gross proceeds over $56M from institutional and individual investors as well as BioNTech and The Leukemia & Lymphoma Society (LLS).
We value investor communications very highly and we build our investor relationships on trust and transparency. Ryvu is audited by EY and is subject to regulatory oversight of the Polish Financial Supervisory Authority, under the European Union and the Polish laws. Ryvu technological expertise is validated by global partnerships with BioNTech, Exelixis, Galapagos, Leukemia & Lymphoma Society, Menarini Group, and Merck KGaA.
In 2016, Ryvu has spun out its NALP3 inflammasome assets to NodThera, founded by life science investor, Epidarex Capital. In total, the project aimed at the development of inflammasome inhibitors discovered by Ryvu and spun off to NodThera, has already raised over £80 million (over $98 million) of funding. Ryvu remains a shareholder in the Company. For more information about NodThera see: www.nodthera.com.
In August 2022, Ryvu has received €22 million in financing from The European Investment Bank (EIB) to accelerate the development of new therapies to treat severe blood cancers and solid tumours, including further clinical development of the flagship project RVU120.